# CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke

> **NCT07709845** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Clarion Cells, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Chronic Ischemic Stroke

## Interventions

- **BIOLOGICAL:** CC-101 (f/k/a NR1) Intracerebral Transplantation
- **DRUG:** Tacrolimus
- **PROCEDURE:** Sham Surgical Control

## Key facts

- **NCT ID:** NCT07709845
- **Lead sponsor:** Clarion Cells, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709845, "CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*